A randomised placebo-controlled trial of combined mitochondrial agents for the treatment of fatigue and depression in multiple sclerosis with an assessment of the impact on kynurenine pathway metabolomics

Recent work implicates mitochondrial function problems as determinants of brain damage and symptoms in multiple sclerosis. Mitochondria are the powerhouses of brain cells and they are very vulnerable to oxidant damage. Specific antioxidant regimens can rescue damaged mitochondria. This clinical trial will evaluate how a newly developed Australian combined mitochondrial therapy alleviates fatigue and depression among people with relapsing remitting multiple sclerosis and fatigue.